Sign in
Not yet taking people in NetherlandsPhase 3

Tests a shorter course of immunotherapy in people with advanced lung cancer

Tests stopping immunotherapy early in adults with advanced non-small cell lung cancer.

Key facts

Who runs it
Leids Universitair Medisch Centrum (LUMC)
Where
's-Gravenhage, Amsterdam, Apeldoorn, Dirksland, Dordrecht, and Leiden, NetherlandsSee the 6 sites
Registry title
A phase III trial of a De-escalated Immune-strategy During first-line treAtment in patients with metastatic non-small Cell lung cancer (NSCLC): DIDaC
Status
Not yet recruiting
Phase
Phase 3
People taking part
500 people, planned
Started
1 Aug 2025
Expected to end
1 Aug 2031
Type of study
Interventional
Record updated
12 September 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with stage IV (metastatic) non-small cell lung cancer. They must have had about 6 months of first-line immunotherapy, with or without chemotherapy, and the cancer has not grown.

Age
18 years or older
Sex
All sexes can join
Disease stage
Advanced, metastatic non-small cell lung cancer, UICC stage IV
Earlier treatment
Must have had first-line immunotherapy or first-line chemo-immunotherapy for 6 months (plus or minus 2 weeks). No other systemic anti-cancer treatment for this disease.

Main reasons for not taking part

  • Other systemic anti-cancer treatment for this disease besides first-line (chemo-)immunotherapy
  • Any contraindication (as per label) for immune checkpoint inhibitors
  • Cancer that has grown: response or stable disease is required, on imaging no older than 3 weeks
  • ECOG performance status above 2, or not fit and willing to continue treatment

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Advanced, metastatic non-small cell lung cancer UICC stage IV
  • Having received first line immunotherapy or first line (chemo)immunotherapy for 6 months ±2 weeks
  • Response or stable disease according to RECIST 1.1 as determined by imaging no older than 3 weeks at moment of randomization
  • Signed and dated informed consent
  • ECOG PS 0-2 and fit and willing to continue treatment with first line (chemo-)immunotherapy as deemed by the treating physician

Who cannot take part

  • Any contra-indication (as per label) for treatment with immune checkpoint inhibitors
  • Other systemic anti-cancer treatment for the disease under study other than the first line (chemo-)immunotherapy

Where in Netherlands

  • Haga Hospital's-Gravenhage, NetherlandsNot yet recruiting
  • Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingAmsterdam, NetherlandsNot yet recruiting
  • Gelre HospitalsApeldoorn, NetherlandsNot yet recruiting
  • Het Van Weel-Bethesda ZiekenhuisDirksland, NetherlandsNot yet recruiting
  • Albert Schweitzer ZiekenhuisDordrecht, NetherlandsNot yet recruiting
  • Leids Universitair Medisch Centrum (LUMC)Leiden, NetherlandsNot yet recruiting

About the trial

What the trial wants to find out

To evaluate the efficacy of shorter duration of standard of care treatment ([chemo]immunotherapy) for patients with metastatic NSCLC

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
A phase III trial of a De-escalated Immune-strategy During first-line treAtment in patients with metastatic non-small Cell lung cancer (NSCLC): DIDaC
Plain-language title
Tests a shorter course of immunotherapy in people with advanced lung cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
12 September 2025